Immuno-Oncology | Specialty

Dr. Nghiem on Immunotherapy in Merkel Cell Carcinoma

July 25th 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses immunotherapy for the treatment of Merkel cell carcinoma.

Frontline Pembrolizumab Improves Survival in HNSCC

July 25th 2018

Pembrolizumab (Keytruda) significantly improved overall survival compared with the standard frontline regimen of cetuximab (Erbitux) plus platinum chemotherapy and 5-FU in patients with recurrent or metastatic HNSCC.

Targeted Therapies Emerging for Less-Common NSCLC Subtypes

July 25th 2018

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

Biomarkers for Frontline Immunotherapy Pose Obstacles in NSCLC

July 25th 2018

John A. Kosteva, MD, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer.

Dr. Weber Discusses Updated Data for CheckMate-238

July 24th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Langer Highlights the Impact of Chemoimmunotherapy in NSCLC

July 24th 2018

Although impressive single-agent data have been seen with agents such as pembrolizumab (Keytruda) versus chemotherapy in a high–PD-L1 population, the combination of PD-L1 inhibitors and chemotherapy may prove to be beneficial in a broader group of patients.

Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma

July 23rd 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Novel Combinations Advance Through RCC Pipeline

July 20th 2018

Peter J. Van Veldhuizen, MD, discusses available and emerging therapies for patients with kidney cancer.

Atezolizumab Regimen Extends PFS in Frontline Nonsquamous NSCLC

July 19th 2018

Adding atezolizumab to pemetrexed and cisplatin or carboplatin in the frontline setting reduced the risk of disease progression or death versus chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer, according to findings from the phase III IMpower132 study.

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer

July 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Ramalingam Reflects on Recent Advances in SCLC

July 17th 2018

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

Dr. West Discusses Latest Immunotherapy Findings in Lung Cancer

July 17th 2018

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma

July 15th 2018

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

July 13th 2018

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

State of Immunotherapy Continues to Shift in NSCLC

July 13th 2018

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11th 2018

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

July 10th 2018

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Highlights Atezolizumab/Bevacizumab Combo in RCC

July 6th 2018

Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.